Canaccord Adams initiates coverage on Bionovo (Nasdaq: BNVI) with a Buy rating and $3.50 price target.

Bionovo is ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE